Border to Coast Pensions Partnership Ltd Raises Holdings in Danaher Corporation $DHR

Border to Coast Pensions Partnership Ltd boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 31.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 204,350 shares of the conglomerate’s stock after acquiring an additional 48,437 shares during the period. Border to Coast Pensions Partnership Ltd’s holdings in Danaher were worth $40,514,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Tyche Wealth Partners LLC purchased a new position in Danaher in the third quarter valued at about $462,000. Ceredex Value Advisors LLC grew its stake in Danaher by 1.6% during the 2nd quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock valued at $49,262,000 after purchasing an additional 3,862 shares in the last quarter. Weitz Investment Management Inc. increased its stake in shares of Danaher by 6.1% in the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after buying an additional 30,300 shares during the last quarter. Lockheed Martin Investment Management Co. lifted its position in shares of Danaher by 49.4% during the third quarter. Lockheed Martin Investment Management Co. now owns 25,340 shares of the conglomerate’s stock worth $5,024,000 after purchasing an additional 8,380 shares during the last quarter. Finally, Nvwm LLC grew its position in shares of Danaher by 20.4% in the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after acquiring an additional 1,204 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Danaher news, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 30,248 shares of company stock valued at $6,609,663. Company insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on DHR shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Monday, December 29th. JPMorgan Chase & Co. raised their price target on Danaher from $270.00 to $275.00 and gave the company an “overweight” rating in a report on Thursday, January 29th. The Goldman Sachs Group dropped their price objective on Danaher from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday, January 29th. Jefferies Financial Group upped their price target on Danaher from $255.00 to $265.00 and gave the company a “buy” rating in a report on Wednesday, January 28th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Danaher in a report on Thursday, January 29th. Twenty analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.32.

Danaher Stock Up 1.3%

DHR opened at $219.31 on Thursday. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $242.80. The business has a 50 day moving average of $230.07 and a 200-day moving average of $214.68. The stock has a market capitalization of $154.91 billion, a price-to-earnings ratio of 43.51, a P/E/G ratio of 2.93 and a beta of 0.91.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The firm had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. During the same quarter in the previous year, the company earned $2.14 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Friday, December 26th were issued a $0.32 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 25.40%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.